229 related articles for article (PubMed ID: 12577243)
21. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
[TBL] [Abstract][Full Text] [Related]
22. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
[TBL] [Abstract][Full Text] [Related]
23. Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha.
Koukourakis MI; Giatromanolaki A; Chong W; Simopoulos C; Polychronidis A; Sivridis E; Harris AL
Cancer Chemother Pharmacol; 2004 Jan; 53(1):8-14. PubMed ID: 14574457
[TBL] [Abstract][Full Text] [Related]
24. Future development of amifostine as a radioprotectant.
Werner-Wasik M
Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy.
Koukourakis MI; Giatromanolaki A; Danielidis V; Sivridis E
Int J Radiat Biol; 2008 Jan; 84(1):47-52. PubMed ID: 17852557
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
27. Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?
Rosenman J
Semin Oncol; 2004 Dec; 31(6 Suppl 18):52-8. PubMed ID: 15726524
[TBL] [Abstract][Full Text] [Related]
28. [Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection].
Huang R; Yu H; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2002 Dec; 19(4):708-11. PubMed ID: 12561384
[TBL] [Abstract][Full Text] [Related]
29. Postoperative accelerated radiotherapy with cytoprotection followed by three-dimensional conformal boost in patients with early endometrial/cervical cancer.
Koukourakis MI; Tsoutsou PG; Abatzoglou I; Soulimioti G; Sismanidou K; Liberis V; Giatromanolaki A; Sivridis E; Galazios G
Tumori; 2009; 95(4):455-60. PubMed ID: 19856656
[TBL] [Abstract][Full Text] [Related]
30. Computed tomography assessment of lung density in patients with lung cancer treated with accelerated hypofractionated radio-chemotherapy supported with amifostine.
Koukourakis MI; Tsoutsou PG; Abatzoglou I
Am J Clin Oncol; 2009 Jun; 32(3):258-61. PubMed ID: 19349852
[TBL] [Abstract][Full Text] [Related]
31. Cytoprotection for radiation-associated normal tissue injury.
Mao J; Fatunase OA; Marks LB
Cancer Treat Res; 2008; 139():307-27. PubMed ID: 18236722
[No Abstract] [Full Text] [Related]
32. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
33. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine.
Mehta MP
Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):14-6. PubMed ID: 9794996
[TBL] [Abstract][Full Text] [Related]
34. Randomized trials of amifostine and radiotherapy: effect on survival?
Bourhis J; Thephamongkhol K; Pignon JP
Semin Oncol; 2004 Dec; 31(6 Suppl 18):62-6. PubMed ID: 15726526
[TBL] [Abstract][Full Text] [Related]
35. The potential influence of cell protectors for dose escalation in cancer therapy: an analysis of amifostine.
McCumber LM
Med Dosim; 2004; 29(2):139-43. PubMed ID: 15191764
[TBL] [Abstract][Full Text] [Related]
36. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Mehta V
Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
[TBL] [Abstract][Full Text] [Related]
37. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
Phillips GL
Semin Oncol; 2002 Dec; 29(6 Suppl 19):53-6. PubMed ID: 12577245
[TBL] [Abstract][Full Text] [Related]
38. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
Marcu LG
Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
[TBL] [Abstract][Full Text] [Related]
39. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
40. Exploring the possibility of unique molecular, biological, and tissue effects with hypofractionated radiotherapy.
Story M; Kodym R; Saha D
Semin Radiat Oncol; 2008 Oct; 18(4):244-8. PubMed ID: 18725111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]